Connected injectable drug delivery devices reminds and records patients dosing pattern and makes it accessible to healthcare professionals for significant understanding about the patient condition.
Growing prevalence of chronic diseases like diabetes, cardiovascular disease, and cancer coupled with increasing compliance to the treatment owing to use of the Connected injectable drug delivery devices.

The global Connected Injectable Drug Delivery Devices market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Connected Injectable Drug Delivery Devices volume and value at global level, regional level and company level. From a global perspective, this report represents overall Connected Injectable Drug Delivery Devices market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Connected Injectable Drug Delivery Devices in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Connected Injectable Drug Delivery Devices manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Phillips-Medisize
West Pharmaceutical Services
Biocorp
Aterica
Unilife
Propeller Health
Haselmeier
SHL
Becton Dickinson
Baxter International
Scandinavian Health
Ypsomed
Terumo Medical
Schott
Owen Mumford
Antares Pharma
Zogenix

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Conventional
Self-Injection
Others

Segment by Application
Diabetes
Cardiovascular Diseases
Autoimmune Diseases
Hormones Replacement
Neurology
Addiction
Respiratory Diseases
Others